Adaptive Biotechnologies
Facts
- HQ
- Seattle
- Sectors
- Biotech, Immune medicine, Diagnostics
- Founded
- 2009 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Adaptive Biotechnologies Corporation Seattle business license
- Stage
- Public
Accolade exits GeekWire 200 after $220M IPO at $1.2B valuation; PNW health techs climb as VC funding hits $2.3B in H1 2020
GeekWire’s latest GeekWire 200 update shows health tech startups rising in the Pacific Northwest rankings during the pandemic, highlighted by Accolade’s $220M IPO at a $1.2B valuation and a surge in VC activity ($2.3B across 135 deals in H1 2020).
Accolade files IPO to sell 8.75M shares at $19–$21, seeks up to $211M and ~$1B valuation; will trade as ACCD
Accolade priced 8.75 million IPO shares at $19–$21 to raise up to $211 million, aiming for a ~ $1 billion valuation and Nasdaq ticker ACCD, positioning itself as Seattle's first public company of 2020. The health benefits platform reported $132.5 million revenue and a $51.3 million net loss for the fiscal year ending Feb. 29, serves 1.6 million members across 58 corporate customers, and estimates a $24 billion total addressable market.
Docugami doubles to 20 after $10M funding and keeps hiring amid widespread tech layoffs
Docugami, a Kirkland, Washington document-engineering startup, doubled its staff to 20 after a $10 million funding round in early February and continues hiring despite widespread tech layoffs. CEO Jean Paoli and new head of operations Hartley Riedner have onboarded remotely, reflecting a flipped labor market where some startups can recruit while larger firms cut jobs.
